NADAC acquisition cost data for FELBAMATE 600 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 47781055101 | $1.35 | 2022-08-17 | Rx |
| 47781063001 | $1.44 | 2022-12-21 | Rx |
| 51525043101 | $1.44 | 2022-12-21 | Rx |
| 51672418601 | $1.44 | 2022-12-21 | Rx |
| 53746073518 | $1.44 | 2022-12-21 | Rx |
| 53746073590 | $1.44 | 2022-12-21 | Rx |
| 62559073101 | $1.44 | 2022-12-21 | Rx |
| 65162073503 | $1.44 | 2022-12-21 | Rx |
| 65162073509 | $1.44 | 2022-12-21 | Rx |
| 65162073518 | $1.44 | 2022-12-21 | Rx |
Generic: Felbamate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $14.3M | 24,436 | 2,614 | $3.19 |
| 2020 | $13.6M | 24,443 | 2,643 | $2.94 |
| 2021 | $13.4M | 24,181 | 2,684 | $2.92 |
| 2022 | $12.7M | 23,754 | 2,679 | $2.77 |
| 2023 | $11.3M | 23,542 | 2,759 | $2.38 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Minnesota | $1.3M | 2,493 | 291 |
| New York | $944.5K | 1,979 | 236 |
| California | $834.3K | 1,466 | 200 |
| Texas | $645.7K | 1,342 | 183 |
| Ohio | $595.8K | 1,099 | 136 |
| Pennsylvania | $566.1K | 1,146 | 126 |
| Wisconsin | $516.0K | 996 | 105 |
| Illinois | $447.2K | 885 | 101 |
| New Jersey | $350.0K | 640 | 81 |
| Florida | $313.6K | 714 | 104 |
| Nebraska | $260.7K | 624 | 65 |
| Missouri | $237.9K | 610 | 70 |
| Michigan | $235.2K | 465 | 63 |
| Indiana | $227.2K | 480 | 60 |
| North Carolina | $217.4K | 467 | 65 |
| Washington | $211.7K | 496 | 57 |
| Tennessee | $201.6K | 376 | 50 |
| Alabama | $187.4K | 476 | 62 |
| South Carolina | $177.5K | 356 | 48 |
| Virginia | $175.9K | 332 | 49 |
| Kansas | $175.0K | 368 | 42 |
| Kentucky | $159.8K | 231 | 31 |
| Georgia | $154.8K | 315 | 48 |
| Iowa | $149.8K | 324 | 38 |
| Oregon | $148.0K | 366 | 51 |
| Colorado | $143.1K | 406 | 60 |
| Massachusetts | $136.5K | 351 | 38 |
| Idaho | $122.8K | 312 | 36 |
| Arizona | $119.1K | 256 | 37 |
| Maine | $117.4K | 276 | 34 |
| Louisiana | $108.8K | 217 | 31 |
| Connecticut | $107.8K | 242 | 34 |
| Arkansas | $106.1K | 315 | 34 |
| Maryland | $100.1K | 163 | 26 |
| North Dakota | $89.7K | 230 | 29 |
| Oklahoma | $80.1K | 272 | 30 |
| Mississippi | $78.8K | 221 | 23 |
| New Hampshire | $71.9K | 142 | 21 |
| Puerto Rico | $59.0K | 116 | 16 |
| Utah | $56.9K | 119 | 15 |
| West Virginia | $53.0K | 114 | 17 |
| Montana | $49.4K | 161 | 16 |
| Vermont | $47.8K | 97 | N/A |
| Nevada | $37.7K | 91 | 14 |
| New Mexico | $32.4K | 72 | N/A |
| South Dakota | $31.9K | 102 | 14 |
| Rhode Island | $23.0K | 53 | N/A |
| District of Columbia | $21.2K | 27 | N/A |
| Wyoming | $10.7K | 40 | N/A |
| Delaware | $9.5K | 31 | N/A |
| Hawaii | $8.3K | 16 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.